<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:xhtml="http://www.w3.org/1999/xhtml">
    <url>
        <loc>https://www.isino.com/index.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/index.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/index.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/index.html"/>
        <changefreq>daily</changefreq>
        <priority>1.0</priority>
    </url>
    <url>
        <loc>https://www.isino.com/marketplace.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/marketplace.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/marketplace.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/marketplace.html"/>
        <changefreq>weekly</changefreq>
        <priority>0.9</priority>
    </url>
    <url>
        <loc>https://www.isino.com/supply.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/supply.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/supply.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/supply.html"/>
        <changefreq>weekly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/demand.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/demand.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/demand.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/demand.html"/>
        <changefreq>weekly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insights.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insights.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insights.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insights.html"/>
        <changefreq>daily</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/about.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/about.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/about.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/about.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/services.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/services.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/services.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/services.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/network.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/network.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/network.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/network.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/credentials.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/credentials.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/credentials.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/credentials.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/clients.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/clients.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/clients.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/clients.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.8</priority>
    </url>
    <url>
        <loc>https://www.isino.com/contact.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/contact.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/contact.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/contact.html"/>
        <changefreq>monthly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/join.html</loc>
        <lastmod>2026-11-22</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/join.html"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/join.html"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/join.html"/>
        <changefreq>yearly</changefreq>
        <priority>0.6</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=remege-vor-bio-rc298-license-amendment-warrants</loc>
        <lastmod>2026-11-13</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=remege-vor-bio-rc298-license-amendment-warrants"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=remege-vor-bio-rc298-license-amendment-warrants"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=remege-vor-bio-rc298-license-amendment-warrants"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=lilly-orforglipron-nmpa-oral-glp1-weight-management</loc>
        <lastmod>2026-11-12</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=lilly-orforglipron-nmpa-oral-glp1-weight-management"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=lilly-orforglipron-nmpa-oral-glp1-weight-management"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=lilly-orforglipron-nmpa-oral-glp1-weight-management"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=argenx-unnatural-products-115b-ai-peptide-acquisition</loc>
        <lastmod>2026-11-09</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=argenx-unnatural-products-115b-ai-peptide-acquisition"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=argenx-unnatural-products-115b-ai-peptide-acquisition"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=argenx-unnatural-products-115b-ai-peptide-acquisition"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=vgx-3100-dna-hpv-vaccine-phase3-sitc-lba</loc>
        <lastmod>2026-11-07</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=vgx-3100-dna-hpv-vaccine-phase3-sitc-lba"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=vgx-3100-dna-hpv-vaccine-phase3-sitc-lba"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=vgx-3100-dna-hpv-vaccine-phase3-sitc-lba"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=beigene-q3-2026-19b-revenue-guidance-third-raise</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=beigene-q3-2026-19b-revenue-guidance-third-raise"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=beigene-q3-2026-19b-revenue-guidance-third-raise"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=beigene-q3-2026-19b-revenue-guidance-third-raise"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=cms-mfp-permanent-framework-final-rule</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=cms-mfp-permanent-framework-final-rule"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=cms-mfp-permanent-framework-final-rule"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=cms-mfp-permanent-framework-final-rule"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=nmpa-november-2026-approval-batch</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=nmpa-november-2026-approval-batch"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=nmpa-november-2026-approval-batch"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=nmpa-november-2026-approval-batch"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=jnj-rybrevant-faspro-hnscc-fda-approval</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=jnj-rybrevant-faspro-hnscc-fda-approval"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=jnj-rybrevant-faspro-hnscc-fda-approval"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=jnj-rybrevant-faspro-hnscc-fda-approval"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=sino-biopharm-boehringer-7b-adc-tce-licensing</loc>
        <lastmod>2026-11-04</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=sino-biopharm-boehringer-7b-adc-tce-licensing"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=sino-biopharm-boehringer-7b-adc-tce-licensing"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=sino-biopharm-boehringer-7b-adc-tce-licensing"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=astrazeneca-rhythm-10b-nonbinding-bid</loc>
        <lastmod>2026-11-04</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=astrazeneca-rhythm-10b-nonbinding-bid"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=astrazeneca-rhythm-10b-nonbinding-bid"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=astrazeneca-rhythm-10b-nonbinding-bid"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=ivonescimab-esmo-2026-phase3-double-positive</loc>
        <lastmod>2026-10-28</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=ivonescimab-esmo-2026-phase3-double-positive"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=ivonescimab-esmo-2026-phase3-double-positive"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=ivonescimab-esmo-2026-phase3-double-positive"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=gsk-hibsago-bepirovirsen-chronic-hepatitis-b</loc>
        <lastmod>2026-10-20</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=gsk-hibsago-bepirovirsen-chronic-hepatitis-b"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=gsk-hibsago-bepirovirsen-chronic-hepatitis-b"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=gsk-hibsago-bepirovirsen-chronic-hepatitis-b"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=hansoh-roche-15-5b-adc-deal</loc>
        <lastmod>2026-10-20</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=hansoh-roche-15-5b-adc-deal"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=hansoh-roche-15-5b-adc-deal"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=hansoh-roche-15-5b-adc-deal"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=merck-kgaa-silence-1-3b-acquisition</loc>
        <lastmod>2026-10-19</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=merck-kgaa-silence-1-3b-acquisition"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=merck-kgaa-silence-1-3b-acquisition"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=merck-kgaa-silence-1-3b-acquisition"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=mofcom-48th-catalog-biotech-export-controls</loc>
        <lastmod>2026-10-17</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=mofcom-48th-catalog-biotech-export-controls"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=mofcom-48th-catalog-biotech-export-controls"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=mofcom-48th-catalog-biotech-export-controls"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=platform-mipt-insight-center-weekly-2026w46</loc>
        <lastmod>2026-11-15</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=platform-mipt-insight-center-weekly-2026w46"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=platform-mipt-insight-center-weekly-2026w46"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=platform-mipt-insight-center-weekly-2026w46"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=windward-bio-nasdaq-ipo-225m-net-proceeds</loc>
        <lastmod>2026-11-14</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=windward-bio-nasdaq-ipo-225m-net-proceeds"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=windward-bio-nasdaq-ipo-225m-net-proceeds"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=windward-bio-nasdaq-ipo-225m-net-proceeds"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=obi-pharma-novartis-adc-platform-300m-upfront</loc>
        <lastmod>2026-11-13</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=obi-pharma-novartis-adc-platform-300m-upfront"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=obi-pharma-novartis-adc-platform-300m-upfront"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=obi-pharma-novartis-adc-platform-300m-upfront"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=abbvie-upadacitinib-vitiligo-nmpa-china-approval</loc>
        <lastmod>2026-11-13</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=abbvie-upadacitinib-vitiligo-nmpa-china-approval"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=abbvie-upadacitinib-vitiligo-nmpa-china-approval"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=abbvie-upadacitinib-vitiligo-nmpa-china-approval"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=nmpa-cgt-review-optimization-api-transfer-regulation</loc>
        <lastmod>2026-11-13</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=nmpa-cgt-review-optimization-api-transfer-regulation"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=nmpa-cgt-review-optimization-api-transfer-regulation"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=nmpa-cgt-review-optimization-api-transfer-regulation"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=az-pfizer-durvalumab-padcev-volga-miibc-perioperative-approval</loc>
        <lastmod>2026-11-13</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=az-pfizer-durvalumab-padcev-volga-miibc-perioperative-approval"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=az-pfizer-durvalumab-padcev-volga-miibc-perioperative-approval"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=az-pfizer-durvalumab-padcev-volga-miibc-perioperative-approval"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=toqiji-pharma-40m-series-a-bispecific-adc</loc>
        <lastmod>2026-11-12</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=toqiji-pharma-40m-series-a-bispecific-adc"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=toqiji-pharma-40m-series-a-bispecific-adc"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=toqiji-pharma-40m-series-a-bispecific-adc"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=yiling-qitongtongbi-tcm-innovative-drug-ra-approval</loc>
        <lastmod>2026-11-12</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=yiling-qitongtongbi-tcm-innovative-drug-ra-approval"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=yiling-qitongtongbi-tcm-innovative-drug-ra-approval"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=yiling-qitongtongbi-tcm-innovative-drug-ra-approval"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=kyverna-miv-cel-bla-first-autoimmune-cart-sps</loc>
        <lastmod>2026-11-12</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=kyverna-miv-cel-bla-first-autoimmune-cart-sps"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=kyverna-miv-cel-bla-first-autoimmune-cart-sps"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=kyverna-miv-cel-bla-first-autoimmune-cart-sps"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=heyue-pimicotinib-fda-approval-tgct-merck-license</loc>
        <lastmod>2026-11-11</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=heyue-pimicotinib-fda-approval-tgct-merck-license"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=heyue-pimicotinib-fda-approval-tgct-merck-license"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=heyue-pimicotinib-fda-approval-tgct-merck-license"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=bayer-asundexian-fda-approval-fxia-stroke-prevention</loc>
        <lastmod>2026-11-10</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=bayer-asundexian-fda-approval-fxia-stroke-prevention"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=bayer-asundexian-fda-approval-fxia-stroke-prevention"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=bayer-asundexian-fda-approval-fxia-stroke-prevention"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=pbgene-hbv-aasld-2026-cccdata-elimination</loc>
        <lastmod>2026-11-08</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=pbgene-hbv-aasld-2026-cccdata-elimination"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=pbgene-hbv-aasld-2026-cccdata-elimination"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=pbgene-hbv-aasld-2026-cccdata-elimination"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=china-nrdl-2026-car-t-first-negotiation-catalog</loc>
        <lastmod>2026-11-06</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=china-nrdl-2026-car-t-first-negotiation-catalog"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=china-nrdl-2026-car-t-first-negotiation-catalog"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=china-nrdl-2026-car-t-first-negotiation-catalog"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=qyuns-caldera-tl1a-il17-bispecific-780m-second-deal</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=qyuns-caldera-tl1a-il17-bispecific-780m-second-deal"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=qyuns-caldera-tl1a-il17-bispecific-780m-second-deal"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=qyuns-caldera-tl1a-il17-bispecific-780m-second-deal"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
    <url>
        <loc>https://www.isino.com/insight.html?slug=hinova-evommune-hp570-vav1-molecular-glue-1-1b</loc>
        <lastmod>2026-11-05</lastmod>
        <xhtml:link rel="alternate" hreflang="zh-CN" href="https://www.isino.com/insight.html?slug=hinova-evommune-hp570-vav1-molecular-glue-1-1b"/>
        <xhtml:link rel="alternate" hreflang="en" href="https://www.isino.com/en/insight.html?slug=hinova-evommune-hp570-vav1-molecular-glue-1-1b"/>
        <xhtml:link rel="alternate" hreflang="x-default" href="https://www.isino.com/insight.html?slug=hinova-evommune-hp570-vav1-molecular-glue-1-1b"/>
        <changefreq>weekly</changefreq>
        <priority>0.7</priority>
    </url>
</urlset>
